Abliva
ABLI | ST
Overview
Corporate Details
- ISIN(s):
- SE0002575340
- LEI:
- 5493005YV22OTMUHZ183
- Country:
- Sweden
- Address:
- Medicon Village, 223 81 Lund
- Website:
- https://abliva.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-03 13:10 |
Delisting Announcement
Delisting of the shares of Abliva: last day of trading 17 March 2025
|
English | 64.3 KB | |
| 2025-03-03 13:10 |
Delisting Announcement
Avnotering av aktierna i Abliva: sista handelsdag 17 mars 2025
|
Swedish | 64.1 KB | |
| 2025-02-26 08:30 |
General Meeting Notice
Notice of Extraordinary General Meeting in Abliva AB (publ)
|
English | 74.8 KB | |
| 2025-02-26 08:30 |
General Meeting Notice
Kallelse till extra bolagsstämma i Abliva AB (publ)
|
Swedish | 75.2 KB | |
| 2025-02-25 09:50 |
Delisting Announcement
Abliva applies for delisting and will convene an extraordinary general meeting
|
English | 64.9 KB | |
| 2025-02-25 09:50 |
Delisting Announcement
Abliva ansöker om avnotering och kommer att kalla till extra bolagsstämma
|
Swedish | 65.1 KB | |
| 2025-02-21 14:41 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.6 KB | |
| 2025-02-21 08:30 |
Interim Report
|
Swedish | 2.6 MB | |
| 2025-02-21 08:30 |
Earnings Release
|
English | 2.6 MB | |
| 2025-02-12 11:37 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.5 KB | |
| 2025-02-11 15:52 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.7 KB | |
| 2024-12-15 20:00 |
Takeover Announcement Report
Uttalande från Ablivas styrelse med anledning av Pharmings kontanta offentliga …
|
Swedish | 83.3 KB | |
| 2024-12-15 20:00 |
Takeover Announcement Report
Statement by the Board of Directors of Abliva regarding the public cash offer f…
|
English | 80.9 KB | |
| 2024-11-29 18:00 |
Quarterly Report
|
Swedish | 2.9 MB | |
| 2024-11-29 18:00 |
Earnings Release
|
English | 2.9 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-07 | David Bejker | Other | Sell | 269,005 | 121,052.25 SEK |
| 2024-05-31 | Catharina Janzon Johansson | Other | Other | 2,000,000 | 60,000.00 SEK |
| 2024-05-28 | David Laskow-Pooley | Other | Other | 1,000,000 | 30,000.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 54,128 | 11,664.58 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 38,000 | 8,151.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 36,064 | 7,807.86 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 15,091 | 3,267.20 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,901 | 2,588.47 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,270 | 2,479.40 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,275 | 2,474.86 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
SenzaGen AB | Sweden | SENZA | |
|
SoftOx Solutions AS | Norway | SOFTX | |
|
Spago Nanomedical AB | Sweden | SPAGO | |
/other/Spermosens_AB_publ-logo.jpg?Expires=1751277047&Signature=hPys3q1xGdVN~2MgnzsJUb00qjqyqI62~0-qdElWq~Hh5GaQqiuoW4sj0C2b8KcH9VqVIn8lTjDWuQUzoXBBJixqv94y6SaVBnffo8~WHjBo4DnIhUtL8VeyaFl6uQ2q9zVHhDil7NSB7eIR6bDuh6aD0TvtKhL46PRnmfu2e4ChVXC8KzH5KoXomEM3uxyisGvgGhKGC2C9OfIj8CuOhsFGcI73dDCk2LaePbDDrkAXenSX0z0IYC-QyAEx6B2vh0edEBSmUNeFXeIbtB3Kfpid452ge7QbixNdmPJfRH2ehL6588cRMSbllZaABnYcmTP6Y16f0cxWzlvLys4~hQ__&Key-Pair-Id=K6QMJA61RGOXQ){kind=logo}
|
Spermosens AB (publ) | Sweden | SPERM | |
|
Spexis AG | Switzerland | SPEX | |
|
Sprint Bioscience | Sweden | SPRINT | |
|
Stayble Therapeutics AB | Sweden | STABL | |
|
Stem Cells Spin Spolka Akcyjna | Poland | SCS | |
|
Strategic Partners A/S | Denmark | STRAP | |
|
STRIX GROUP PLC | Isle of Man | KETL |